LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
21 funds hold it · Insiders net selling
Net selling: insiders sold $1.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $2K to $30K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 9, 2026
Period ending
Sep 30, 2026
Earnings per share
-$0.05 expected
Estimates as of Nov 13, 2026
EPS expected
-$0.09 to $0.00
Revenue expected
4 analysts
Last 30 days
Analysts raising estimates
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 9, 2026 | -$0.09est. -$0.05 | -$0.04miss | $48.8MSEC filing | +52.3%from $32.1M |
| Jun 30, 2026Reported Aug 4, 2026 | -$0.08est. -$0.09 | +$0.01beat | $51.2MSEC filing | +93.9%from $26.4M |
| Mar 31, 2026Reported May 7, 2026 | -$0.08est. -$0.07 | -$0.01miss | $44.2MSEC filing | +167.6%from $16.5M |
| Dec 31, 2025Reported Feb 23, 2026 | -$0.06est. -$0.11 | +45.75%beat | $38.3MAlpha Vantage | +407.0%from $7.6M |
| Sep 30, 2025Reported Nov 5, 2025 | -$0.07est. -$0.10 | +30.00%beat | $32.1MSEC filing | +425.1%from $6.1M |
| Jun 30, 2025Reported Aug 5, 2025 | -$0.10est. -$0.10 | +0.00%in line | $26.4MSEC filing | +2423.9%from $1.0M |
| Mar 31, 2025Reported May 12, 2025 | -$0.15est. -$0.16 | +6.25%beat | $16.5MSEC filing | +41192.5%from $40.0K |
| Dec 31, 2024Reported Mar 3, 2025 | -$0.08est. -$0.13 | +38.46%beat | $7.6MAlpha Vantage | +5333.1%from $139.0K |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $38.3M | $44.2M | $51.2M | $48.8M |
| Cost of what it sold | $4.2M | $238.0K | $298.0K | $1.3M |
| Gross profit | $34.0M | $44.0M | $50.9M | $47.5M |
| What it spent | ||||
| Research and development | $60.8M | $64.8M | $57.7M | $69.0M |
| Sales and admin | $38.7M | $45.8M | $51.8M | $52.5M |
| Other operating costs | — | $3.2M | $3.1M | $4.1M |
| Total operating expenses | $98.7M | $113.8M | $112.6M | $125.5M |
| What was left | ||||
| Operating profit | -$64.7M | -$69.8M | -$61.7M | -$78.0M |
| Interest on debt | $27.2M | $28.5M | $20.0K | $32.0M |
| Profit before tax | -$62.1M | -$632.8M | -$230.4M | -$184.6M |
| Tax | -$135.0K | -$9.0K | — | — |
| Net profit | -$61.9M | -$632.8M | -$230.4M | -$184.6M |
| EBITDA | -$31.0M | -$599.9M | -$226.0M | -$148.7M |
This stock is under pressure.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
ImmunityBio, Inc. (26CA.F) Seasonal Returns Chart - Yahoo Finance
NeutralNov 10Immunitybio Inc earnings missed by $0.10, revenue fell short of estimates
BearishNov 9Why Is ImmunityBio Stock Trading Lower On Monday? - ImmunityBio (NASDAQ:IBRX)
BearishNov 9ImmunityBio posts 53% revenue gain as ANKTIVA wins label expansion
BullishNov 9ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
BullishNov 9ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
NeutralNov 9Form 8-K ImmunityBio, Inc. For: Nov 09
BullishNov 9IBRX: ImmunityBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
BullishNov 911 macro signals shaping IBRX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
